drugset / Trial / NCT00232661

PROACT - Pre-Operative Arimidex Compared To Tamoxifen

NCT00232661

Phase 3 Completed 452 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to compare tamoxifen, versus a newer treatment, ARIMIDEX, which we already know to be well tolerated. The main objectives of this research study are to see whether using these drugs will shrink down tumours before surgery and to see if any shrinkage in the tumour affects the extent of surgery that is required.

Timeline

Start
2000-08
Primary completion
2003-01
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Anastrozole Other / unclassified 1 mg
Subject Tamoxifen Small molecule 20 mg

Indications